Publikationen in Zusammenarbeit mit Forschern von Sociedad Española de Reumatología (17)

2024

  1. Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©

    Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2022

  1. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases

    Joint Bone Spine, Vol. 89, Núm. 1

  2. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

2021

  1. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

  2. Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)

    Anales de Pediatria, Vol. 94, Núm. 2, pp. 116.e1-116.e11

2020

  1. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  2. Prevalence of systemic lupus erythematosus in Spain: Higher than previously reported in other countries?

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2556-2562

  3. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 71-86

  4. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: Obstetric Antiphospholipid Syndrome and Special Situations

    Reumatologia Clinica, Vol. 16, Núm. 2P2, pp. 133-148

2019

  1. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 90-96

2018

  1. Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice

    Rheumatology and Therapy, Vol. 5, Núm. 1, pp. 243-253

2017

  1. Development of an activity disease score in patients with uveitis (UVEDAI)

    Rheumatology International, Vol. 37, Núm. 4, pp. 647-656

2015

  1. Erratum to Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis (Rheumatol Int, (2015), 10.1007/s00296-014-3189-6)

    Rheumatology International

  2. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis

    Rheumatology International, Vol. 35, Núm. 7, pp. 1127-1137

2011

  1. An audit of the variability of diagnosis and management of gout in the rheumatology setting: The gout evaluation and management study

    Journal of Clinical Rheumatology, Vol. 17, Núm. 7, pp. 349-355